Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza.
Skillington says the 'early data readout' indicates that the challenge trial was successful.